Trials / Completed
CompletedNCT03149939
Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Febuxostat 40 milligramsTablet | Febuxostat 40 milligramsTablet every other day for 3 months |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-04-01
- Completion
- 2017-05-01
- First posted
- 2017-05-11
- Last updated
- 2017-05-11
Source: ClinicalTrials.gov record NCT03149939. Inclusion in this directory is not an endorsement.